176 related articles for article (PubMed ID: 34978698)
1. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
Lal S; Raffel C
Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
[TBL] [Abstract][Full Text] [Related]
2. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
Lal S; Carrera D; Phillips JJ; Weiss WA; Raffel C
Neuro Oncol; 2018 Nov; 20(12):1606-1615. PubMed ID: 29912438
[TBL] [Abstract][Full Text] [Related]
3. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma.
Studebaker AW; Hutzen B; Pierson CR; Russell SJ; Galanis E; Raffel C
Neuro Oncol; 2012 Apr; 14(4):459-70. PubMed ID: 22307474
[TBL] [Abstract][Full Text] [Related]
5. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.
Hutzen B; Pierson CR; Russell SJ; Galanis E; Raffel C; Studebaker AW
BMC Cancer; 2012 Nov; 12():508. PubMed ID: 23134812
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
7. Treatment of medulloblastoma with a modified measles virus.
Studebaker AW; Kreofsky CR; Pierson CR; Russell SJ; Galanis E; Raffel C
Neuro Oncol; 2010 Oct; 12(10):1034-42. PubMed ID: 20494960
[TBL] [Abstract][Full Text] [Related]
8. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
[TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
10. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
11. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
14. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
15. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
18. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
[TBL] [Abstract][Full Text] [Related]
19. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]